3Kivimaki M, Batty G. D, Singh-Manoux A, etal. Validating the Framingham Hypertension Risk Score results from the White- hall II study[J]. Hypertension,2009, 54(3) :496-501.
4King P, Peacock I, and Donnelly R. The UK prospective diabetes study (UKPDS) t clinical and therapeutic implications for type 2 diabetes[J]. Br J Clin Pharmacol, 1999, 48 (5): 643-648.
5Safar M. E, Blacher J, Staessen J. A. Hypertension Optimal Treatment (HOT) trial[J]. Lancet,1998, 352(9127) :573.
6Calhoun DA,Jones D,Textor S,et al.American Heart Association Professional Education Committee.Resistant hypertension:diagnosis,evaluation,and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J].Circulation,2008 24,117(25):e510-26.
7Julius S,Kjeldsen SE,Brurner H,et al.VALUE trial:Long-term blood pressure trends in13,449 patients with hypertension and high cardiovascular risk[J].Am J Hypertens,2003,16(7):544-8.
8Frishman WH,Hainer JW,Sugg J,et al.A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension CombinationTrial (M-FACT)[J].Am J Hypertens,2006,19(4):388-95.
9Ernst ME,Carter BL,Goerdt C J,et al.Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure[J].Hypertension,2006,47(3):352-8.
10Stergiou GS,Makris T,Papavasiliou M,et al.Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor,a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy[J].J Hypertens,2005,23(4):883-9.
